-$0.65 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter

Equities research analysts expect Proteostasis Therapeutics Inc (NASDAQ:PTI) to announce ($0.65) earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Proteostasis Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.72). Proteostasis Therapeutics posted earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year over year growth rate of 71.1%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 29th.

According to Zacks, analysts expect that Proteostasis Therapeutics will report full-year earnings of ($2.47) per share for the current financial year, with EPS estimates ranging from ($2.56) to ($2.40). For the next financial year, analysts forecast that the company will report earnings of ($2.21) per share, with EPS estimates ranging from ($2.81) to ($1.49). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Proteostasis Therapeutics.

Proteostasis Therapeutics (NASDAQ:PTI) last released its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%.

Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 18th. Leerink Swann restated an “outperform” rating and set a $9.00 price target (down previously from $17.00) on shares of Proteostasis Therapeutics in a research note on Wednesday, August 16th.

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its holdings in Proteostasis Therapeutics by 425.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,124,602 shares of the company’s stock valued at $2,361,000 after purchasing an additional 910,550 shares during the period. Sabby Management LLC boosted its holdings in Proteostasis Therapeutics by 109.6% in the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock valued at $586,000 after purchasing an additional 65,451 shares during the period. Susquehanna International Group LLP bought a new stake in Proteostasis Therapeutics in the 2nd quarter valued at $254,000. Goldman Sachs Group Inc. boosted its holdings in Proteostasis Therapeutics by 364.3% in the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock valued at $243,000 after purchasing an additional 40,731 shares during the period. Finally, Bain Capital Public Equity Management LLC bought a new stake in Proteostasis Therapeutics in the 2nd quarter valued at $1,233,000. Institutional investors and hedge funds own 68.08% of the company’s stock.

Proteostasis Therapeutics (NASDAQ:PTI) opened at $2.52 on Wednesday. Proteostasis Therapeutics has a 12 month low of $1.41 and a 12 month high of $16.67.

ILLEGAL ACTIVITY NOTICE: “-$0.65 Earnings Per Share Expected for Proteostasis Therapeutics Inc (PTI) This Quarter” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/06/0-65-earnings-per-share-expected-for-proteostasis-therapeutics-inc-pti-this-quarter.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Get a free copy of the Zacks research report on Proteostasis Therapeutics (PTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about Proteostasis Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteostasis Therapeutics Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit